- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02963428
Teaching Appropriate Gestational Weight Gain (TAGG)
Přehled studie
Detailní popis
The project is aimed at teaching women about the appropriate weight gain during pregnancy to optimize health outcomes for mothers and newborn babies. Obese gravida meeting inclusion criteria and none of the exclusion criteria will be offered enrollment in TAGG. Those that consent will be randomized to receive standard of care or enhanced care regarding gestational weight gain.
The primary outcome is the proportion of patients that gain less than 20 lbs over the course of the pregnancy. Secondary outcomes include patient knowledge and expectations, attitude about pregnancy weight gain, self-efficacy of ability to eat healthy, and eating, sleeping and physical activity behavior, perceived stress, psychological factors, patient-experience, involvement in care, and food security.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Pennsylvania
-
Danville, Pennsylvania, Spojené státy, 17822
- Geisinger Health System
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
- Dospělý
- Starší dospělý
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Pre-pregnancy body mass index of at least 30 kg/m2 (per patient report of weight)
- Less than 16 weeks gestation
- Gestational weight gain (GWG) less than < 11 pounds from their pre-pregnancy weight to time of potential study enrollment
- Singleton gestation
- Access to a phone
Exclusion Criteria:
- BMI less than 30 kg/m2
- Gestational age greater than or equal to 16 weeks
- Active diagnosis of cancer on their electronic health record problem list
- Acquired immunodeficiency syndrome (AIDS)
- Palliative medicine patients
- Multiple gestations
- GWG in excess of 11 pounds prior to study enrollment
- Patients with Non-Geisinger prenatal care providers
- Vegan diet
- Malabsorptive conditions
- Previously enrolled in TAGG during prior pregnancy. Patient will be excluded from re-randomization
- Non-English Speaking
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Žádný zásah: Standard of Care (SOC)
Participants will receive the usual standard of care which includes written educational materials as well as counseling by their obstetric care provider.
|
|
|
Experimentální: Enhanced Care (EC)
In addition to standard of care, the study participants will also receive: i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy. |
In addition to standard of care, the study participants will also receive: i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy.
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
Gestational weight gain, adjusting for time in the study
Časové okno: at delivery
|
at delivery
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Patient knowledge and expectations factors
Časové okno: Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs.
This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient knowledge and expectations factors.
|
Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
|
Attitude on pregnancy weight gain
Časové okno: Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs.
This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient attitudes on pregnancy weight gain.
|
Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
|
Self-efficacy of healthy eating
Časové okno: Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs.
This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient self-efficacy of healthy eating.
|
Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
|
Eating, sleeping and physical activity behavior
Časové okno: Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs.
This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient eating, sleeping and physical activity behaviors.
|
Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
|
Patient-experience and involvement in care
Časové okno: Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
Participants will be enrolled at baseline (Less than 16 6/7 weeks gestation) and be given a self-report survey tool developed using validated instruments to complete assessing these constructs.
This survey tool will then be administered at 32-34 weeks gestation and 4-12 postpartum assessing end of pregnancy and post-intervention patient experience and involvement in their care.
|
Baseline, 32-34 Weeks Gestation, and 4-12 Weeks Postpartum
|
|
Delivery of large for gestational age infants
Časové okno: At Delivery
|
This measure will be obtained using electronic health record data and analyzed utilizing clinic data points as well as information gathered from patients through self-report survey data.
|
At Delivery
|
|
Diagnosis of gestational diabetes mellitus
Časové okno: Baseline through 4-12 Weeks Postpartum
|
This measure will be obtained using EHR data and analyzed utilizing clinic data points.
|
Baseline through 4-12 Weeks Postpartum
|
|
Neonatal intensive care unit (NICU) admissions
Časové okno: At Delivery
|
At Delivery
|
|
|
Cost of Treatment
Časové okno: Baseline through 4-12 Weeks Postpartum
|
Participant cost of treatment will be assessed utilizing claims data obtained from Geisinger Health Plan to compare the effectiveness of the intervention in reducing cost.
|
Baseline through 4-12 Weeks Postpartum
|
|
Mode of delivery
Časové okno: At Delivery
|
Clinical electronic health record data in regards to the participant mode of delivery will be utilized in statistical analyses to determine whether mode of delivery has an impact on other outcomes of interest.
|
At Delivery
|
|
Rate of gestational weight gain
Časové okno: Baseline through 4-12 weeks postpartum
|
Baseline through 4-12 weeks postpartum
|
|
|
Perceived stress measured via Perceived Stress Scale
Časové okno: Baseline through 4-12 weeks postpartum
|
Perceived Stress will be measured using the Perceived Stress Scale by Cohen et.
al.
|
Baseline through 4-12 weeks postpartum
|
|
Psychological factors measured via Pregnancy Weight Gain Attitude Scale
Časové okno: Baseline through 4-12 Weeks postpartum
|
Psychological factors will be assessed using the Pregnancy Weight Gain Attitude Scale by Palmer et.
al.
|
Baseline through 4-12 Weeks postpartum
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Awathif D Mackeen, MD, MPH, Geisinger Clinic
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2016-0205
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Enhanced Care
-
The Second Hospital of Shandong UniversityAktivní, ne nábor
-
Xuanwu Hospital, BeijingBioray LaboratoriesZatím nenabírámeRoztroušená skleróza | Neuromyelitida Poruchy optického spektra | Chronická zánětlivá demyelinizační polyradikuloneuropatie | Myasthenia Gravis, generalizovanáČína
-
Cellular Biomedicine Group Ltd.The First Affiliated Hospital with Nanjing Medical UniversityDokončenoRefrakterní difúzní velký B-buněčný lymfomČína
-
Stephan Grupp MD PhDChildren's Hospital of Philadelphia; Children's Cancer Research Fund; Alliance...NáborVysoce rizikový neuroblastom | Refrakterní neuroblastom | Recidivující neuroblastomSpojené státy
-
Daniel LandiUkončenoGlioblastom | GliosarkomSpojené státy
-
The Second Hospital of Shandong UniversityAktivní, ne náborBezpečnost a účinnost buněčných léků, objektivní míra odpovědi subjektů atd.Čína
-
Zhejiang UniversityCarbiogene Therapeutics Co. Ltd.NáborPokročilý hepatocelulární karcinomČína
-
Nexcella Inc.Immix Biopharma, Inc.NáborAmyloidóza lehkého řetězce (AL).Spojené státy
-
Second Affiliated Hospital, School of Medicine,...NáborRecidivující a refrakterní B-buněčný lymfomČína
-
Second Affiliated Hospital, School of Medicine,...NáborB-buněčný non Hodgkinův lymfomČína